Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
Authors
Keywords
Immune checkpoint inhibitor, Programmed death 1, Programmed death 1 ligand 1, Chemotherapy, Non-small cell lung carcinoma, Predict
Journal
Journal for ImmunoTherapy of Cancer
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-12-22
DOI
10.1186/s40425-018-0477-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
- (2018) Robert M. Jotte et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
- (2018) Gilberto Lopes et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
- (2018) Enrico Munari et al. Journal of Thoracic Oncology
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
- (2018) Fabio Conforti et al. LANCET ONCOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer
- (2018) Wei You et al. Journal of Cancer
- Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells
- (2018) A. M. Gravett et al. OncoImmunology
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016
- (2018) et al. JAMA Oncology
- Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
- (2018) Chee Khoon Lee et al. JAMA Oncology
- Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
- (2018) Rawad Elias et al. Journal for ImmunoTherapy of Cancer
- 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.
- (2018) Ryan D. Gentzler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).
- (2018) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with
- (2018) Hossein Borghaei et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Nasser Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
- (2017) Zhong-Yi Dong et al. OncoImmunology
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies
- (2017) Jessica Davies et al. PLoS One
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non–Small Cell Lung Carcinoma
- (2016) Kentaro Nakashima et al. Journal of Thoracic Oncology
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma
- (2016) Zhengbo Song et al. LUNG CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy
- (2016) David J. Pinato et al. OncoImmunology
- Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
- (2015) L. Apetoh et al. ANNALS OF ONCOLOGY
- Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
- (2015) J. Peng et al. CANCER RESEARCH
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study
- (2015) Denis Moro-Sibilot et al. LUNG CANCER
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients
- (2015) Shaodong Hong et al. OncoImmunology
- Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
- (2014) A. R. de Biasi et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
- (2014) S. V. Hato et al. CLINICAL CANCER RESEARCH
- A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
- (2010) K. N. Kodumudi et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search